SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 679,939.43 |
| Enterprise Value ($M) | 711,809.83 |
| Book Value ($M) | 14,320.70 |
| Book Value / Share | 15.95 |
| Price / Book | 47.48 |
| NCAV ($M) | -31,703.60 |
| NCAV / Share | -35.31 |
| Price / NCAV | -21.45 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.21 |
| Return on Assets (ROA) | 0.17 |
| Return on Equity (ROE) | 0.82 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.89 |
| Current Ratio | 1.15 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 32,739.70 |
| Assets | 78,714.90 |
| Liabilities | 64,443.30 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 45,042.70 |
| Operating Income | 17,040.00 |
| Net Income | 10,590.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 8,817.90 |
| Cash from Investing | -9,301.50 |
| Cash from Financing | 1,230.10 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Lilly Endowment Inc | 10.10 | -0.90 | |
| 13G/A | Pnc Financial Services Group, Inc. | 5.39 | -0.11 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 547,726 | 2,186,590 | 25.05 | |
| 539,452 | 1,773,533 | 30.42 | |
| 608,779 | 2,776,437 | 21.93 | |
| 424,863 | 2,938,431 | 14.46 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ENZ – Enzo Biochem, Inc. | HYAC – Haymaker Acquisition Corp. 4 |
| JNJ – Johnson & Johnson | MRK – Merck & Co., Inc. |
| NUVB – Nuvation Bio Inc. |